{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:55:43Z","timestamp":1792605343780,"version":"4.5.0"},"reference-count":19,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1001\/jamaoncol.2018.4514","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T15:08:01Z","timestamp":1540566481000},"page":"187","source":"Crossref","is-referenced-by-count":322,"title":["Survival Outcomes in Patients With Previously Untreated\n                    <i>BRAF<\/i>\n                    Wild-Type Advanced Melanoma Treated With Nivolumab Therapy"],"prefix":"10.1001","volume":"5","author":[{"given":"Paolo A.","family":"Ascierto","sequence":"first","affiliation":[{"name":"Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, Sydney, New South Wales, Australia"},{"name":"Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Medical Oncology, Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institute Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Brady","sequence":"additional","affiliation":[{"name":"Medical Oncology and Haematology, Cabrini Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[{"name":"Dermatology Service, University Hospital of Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Di Giacomo","sequence":"additional","affiliation":[{"name":"UOC Oncological Immunotherapy, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[{"name":"Clinique de Dermatologie, Unit\u00e9 d\u2019Onco-Dermatologie, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U1189, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Heidelberg and National Center for Tumor Diseases, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[{"name":"Department of Soft Tissue\/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute\u2013Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"McNeil","sequence":"additional","affiliation":[{"name":"Chris O\u2019Brien Lifehouse, Melanoma Institute Australia, Camperdown, New South Wales"},{"name":"Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Kalinka-Warzocha","sequence":"additional","affiliation":[{"name":"Polish Mother\u2019s Memorial Hospital Research Institute, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela M.","family":"Hernberg","sequence":"additional","affiliation":[{"name":"Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Lebb\u00e9","sequence":"additional","affiliation":[{"name":"Assistance Publique\u2013H\u00f4pitaux de Paris Dermatology and Centre d\u2019Investigation Clinique, University Paris Diderot INSERM U976, Saint Louis Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Charles","sequence":"additional","affiliation":[{"name":"Institute for Advanced Biosciences, Universit\u00e9 Grenoble Alpes\/INSERM U1209\/CNRS UMR 5309 Joint Research Center, Grenoble, France"},{"name":"Dermatology Department, Grenoble Alpes University Hospital, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin","family":"Mihalcioiu","sequence":"additional","affiliation":[{"name":"Department of Oncology, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Chiarion-Sileni","sequence":"additional","affiliation":[{"name":"Melanoma Cancer Unit, Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Mauch","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cognetti","sequence":"additional","affiliation":[{"name":"Division of Oncology, Regina Elena Institute, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ny","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Arance","sequence":"additional","affiliation":[{"name":"Hospital Clinic and Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[{"name":"Center for Cancer Immune Therapy, Herlev Hospital, Herlev, Denmark"},{"name":"Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Essen, Essen, Germany"},{"name":"German Cancer Consortium, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel","family":"Saci","sequence":"additional","affiliation":[{"name":"Global Biometric Sciences, Bristol-Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Jiang","sequence":"additional","affiliation":[{"name":"Global Biometric Sciences, Bristol-Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Oncology Clinical Development, Bristol-Myers Squibb, Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital, University of Queensland, Woolloongabba, Queensland, Australia"},{"name":"Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"coi180086r1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"coi180086r2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"coi180086r3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"coi180086r4","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"coi180086r5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti\u2013CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"coi180086r6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial.","volume":"36","author":"Larkin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"21","key":"coi180086r7","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"coi180086r8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"coi180086r9","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"coi180086r10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"20","key":"coi180086r11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"coi180086r13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"15","key":"coi180086r14","doi-asserted-by":"publisher","first-page":"9503","DOI":"10.1200\/JCO.2016.34.15_suppl.9503","article-title":"Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.","volume":"34","author":"Robert","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10105","key":"coi180086r15","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"issue":"15","key":"coi180086r16","doi-asserted-by":"publisher","first-page":"9504","DOI":"10.1200\/JCO.2017.35.15_suppl.9504","article-title":"Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.","volume":"35","author":"Robert","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi180086r18","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1093\/annonc\/mdt161","article-title":"Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.","volume":"24","author":"Wolchok","year":"2013","journal-title":"Ann Oncol"},{"issue":"11","key":"coi180086r19","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1001\/jamaoncol.2017.1588","article-title":"Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials.","volume":"3","author":"Long","year":"2017","journal-title":"JAMA Oncol"},{"key":"coi180086r17","author":"Atkinson","year":"2015"},{"key":"coi180086r12","unstructured":"NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4.0 Data Files. Bethesda, MD: National Cancer Institute. http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html. Accessed September 13, 2018."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamaoncology\/article-pdf\/5\/2\/187\/17295241\/jamaoncology_ascierto_2018_oi_180086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T11:48:29Z","timestamp":1550144909000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.4514"}},"subtitle":["Three-Year Follow-up of a Randomized Phase 3 Trial"],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.4514","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2,1]]}}}